EDIT logo

EDIT
Editas Medicine Inc

17,064
Mkt Cap
$282.85M
Volume
1.59M
52W High
$4.54
52W Low
$1.18
PE Ratio
-1.56
EDIT Fundamentals
Price
$2.94
Prev Close
$2.89
Open
$2.91
50D MA
$2.21
Beta
2.04
Avg. Volume
1.8M
EPS (Annual)
-$1.80
P/B
10.54
Rev/Employee
$465,747.13
$111.99
Loading...
Loading...
News
all
press releases
Editas Medicine (NASDAQ:EDIT) Downgraded by Wall Street Zen to Sell
Wall Street Zen cut Editas Medicine from a "hold" rating to a "sell" rating in a report on Saturday...
MarketBeat·1h ago
News Placeholder
More News
News Placeholder
Editas (EDIT) Up 3.8% Since Last Earnings Report: Can It Continue?
Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks·3d ago
News Placeholder
Zacks Research Weighs in on Editas Medicine FY2028 Earnings
Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) - Analysts at Zacks Research issued their FY2028 earnings estimates for Editas Medicine in a note issued to investors on Monday, March 23rd. Zacks...
MarketBeat·18d ago
News Placeholder
Editas Medicine, Inc. (NASDAQ:EDIT) Receives Consensus Rating of "Moderate Buy" from Analysts
Shares of Editas Medicine, Inc. (NASDAQ:EDIT - Get Free Report) have been given a consensus rating of "Moderate Buy" by the eight analysts that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, five have...
MarketBeat·23d ago
News Placeholder
Is Editas Medicine Going to $0?
Key PointsEditas Medicine has been on fire over the trailing-12-month period...
Nasdaq News: Markets·24d ago
News Placeholder
Editas Medicine Details In Vivo CRISPR Plan, Targets Year-End Human Proof-of-Concept for EDIT-401
Editas Medicine (NASDAQ:EDIT) executives outlined the company's in vivo CRISPR gene-editing strategy and near-term clinical plans during a recent discussion featuring President and CEO Gilmore...
MarketBeat·27d ago
News Placeholder
Editas Medicine (NASDAQ:EDIT) Upgraded at JonesTrading
JonesTrading raised shares of Editas Medicine from a "hold" rating to a "buy" rating and set a $8.00 price objective on the stock in a research note on Tuesday...
MarketBeat·1mo ago
News Placeholder
EDIT Stock Up on Narrower-Than-Expected Q4 Loss, Revenues Rise Y/Y
Editas stock jumps 16% on reporting a narrower-than-expected Q4 loss and beating revenue estimates while advancing its EDIT-401 gene-editing candidate toward its first human study in 2026.
Zacks·1mo ago
News Placeholder
Editas Medicine (NASDAQ:EDIT) Receives "Buy" Rating from Chardan Capital
Chardan Capital reiterated a "buy" rating and issued a $3.50 price target on shares of Editas Medicine in a report on Monday...
MarketBeat·1mo ago
News Placeholder
Editas Medicine (EDIT) Reports Q4 Loss, Tops Revenue Estimates
Editas (EDIT) delivered earnings and revenue surprises of +77.78% and +280.05%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
<
1
2
...
>

Latest EDIT News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.